Results 101 to 110 of about 58,972 (283)

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective.

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S Alkhatib, Abdulaali R Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A Azzam, Mahmoud H Mosli, Amal M Badawoud, Majed S Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +1 more source

Infliximab to treat Crohn’s disease: an update

, 2011
M Cottone, V CriscuoliBiomedical Department of Internal and Specialist Medicine, Division of Medicine, Villa Sofia-V Cervello Hospital, Palermo University, Palermo, ItalyAbstract: Crohn’s disease (CD) is a chronic inflammatory disease of the ...
Criscuoli V, Cottone M
core  

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease

, 2018
Maochen Zhang,* Tianyu Zhang,* Liwen Hong, Chen Zhang, Jie Zhou, Rong Fan, Lei Wang, Zhengting Wang, Bin Xu, Jie Zhong Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic ...
Hong L, Zhang T, Xu B, Zhang M, Zhang C, Zhong J, Fan R, Wang Z, Zhou J, Wang L   +9 more
core  

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

, 2007
Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases.
Svenson, M., Geborek, P, Bendtzen, K., Saxne, Tore, Svenson, M, Geborek, P., Saxne, T, Bendtzen, K   +7 more
core   +1 more source

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

Food Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso, A. M. Abd El‐Aty, Kwaku Amoah, Xianghong Ju   +3 more
wiley   +1 more source

Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis

, 2009
Pierpaolo Di Micco1,2, Paola Ferrazzi1, Luca Librè1, Loredana Mendolicchio1, Ilaria Quaglia1, Monica De Marco1, Anna Colombo1, Monica Bacci1, Lidia Luciana Rota1, Corrado Lodigiani11Thrombosis Center, Istituto Clinico Humanitas, Rozzano (MI ...
Luca Librè, Paola Ferrazzi, Pierpaolo Di Micco, et al.   +3 more
core  

Infliximab dependency in children with Crohn's disease

, 2009
Udgivelsesdato: 2009-AprBACKGROUND: Recently, infliximab dependency has been described. AIM: To assess frequency of ID in 82 consecutive Crohn's disease children treated with infliximab 2000-2006 and to describe clinical and genetic predictors of long ...
Nevoral, J, Lenicek, M, Larsen, K, Lukas, M, Duricova, D, Pedersen, N, Bronsky, J, Elkjaer, M, Vitek, L, Andersen, P S, Munkholm, P, Hradsky, O, Wewer, V, Adamcova, M   +13 more
core   +1 more source